Pfizer's Market Shift
An activist investor has taken a $1 billion stake in Pfizer, signaling a significant shift in capital flows from COVID-related treatments to GLP-1 weight loss drugs. While Pfizer's stock struggles, companies like Nova Nordisk and Eli Lilly are thriving, with impressive market gains. Pfizer's attempt to enter the GLP-1 market faltered due to adverse trial reactions, highlighting the challenges the pharmaceutical giant faces in a rapidly evolving landscape.In this clip
From this podcast
Prof G Markets
What’s the Biggest Threat to the U.S. Economy’s Soft-Landing? — ft. Mark Zandi | Prof G Markets
Related Questions